Neurophet Honored with Two Awards at the BioSpectrum Asia Excellence Awards 2026

• Receives Awards for MedTech Innovation and AI-Driven Clinical Development; Only Korean Company Recognized in Two Categories
• Recognized for its capabilities in AI-driven clinical support and ICL services, with plans to expand partnerships with global CROs

SEOUL, South Korea, Oct. 14, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has won awards in two categories at the BioSpectrum Asia Excellence Awards 2026.

Neurophet received the Excellence in MedTech Innovation and Excellence in AI-Driven Clinical Development awards, making it the only Korean company recognized in two categories at this year's event.

The dual recognition highlights Neurophet's ability to build on its AI-powered brain imaging solutions, including Neurophet AQUA and Neurophet SCALE PET, and extend its MedTech capabilities into clinical drug development through its Imaging Core Lab (ICL) services, supporting patient selection, imaging biomarker analysis, safety monitoring, and treatment response assessment.

BioSpectrum Asia is a specialized media outlet covering the life sciences industry across the Asia-Pacific region, including pharmaceuticals, biotechnology, medical devices, and digital health. Founded in Singapore in 2006, the publication celebrates its 20th anniversary this year. It reports on leading life sciences companies and industry trends across the Asia-Pacific region, covering research and development (R&D), technological innovation, investment, and business developments.

"This recognition is particularly meaningful as it acknowledges our achievements in continuously expanding our capabilities across the clinical drug development process, building on our accumulated expertise in AI-powered brain imaging analysis and experience in conducting clinical projects through our ICL services," said Jake Junkil Been, Co-CEO of Neurophet.

He added, "Going forward, we will further strengthen our partnerships with global pharmaceutical and biotechnology companies, medical and research institutions, as well as global contract research organizations (CROs) and specialized imaging CROs to expand our ICL services. We will also continue to broaden the application and enhance the value of imaging biomarkers in the development of new treatments for brain disorders."

Neurophet applied for the BioSpectrum Asia Excellence Awards 2026 on Korea Biotechnology Industry Organization (KoreaBIO) recommendation, selecting categories aligned with its technologies and achievements in consultation with the association.

About Neurophet

Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.